Azenta Dividend

Dividend criteria checks 0/6

Azenta does not currently pay a dividend.

Key information

Dividend yield

Payout ratio

Industry average yield	0.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.31
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AZTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZTA's dividend payments have been increasing.

Dividend Yield vs Market

Azenta Dividend Yield vs Market

How does AZTA dividend yield compare to the market?
Segment	Dividend Yield
Company (AZTA)	0%
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Life Sciences)	0.4%
Analyst forecast in 3 Years (AZTA)	0%

Notable Dividend: Unable to evaluate AZTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: AZTA is not paying a notable dividend for the US market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AZTA has not reported any payouts.

Azenta Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Now 20% overvalued

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Consensus EPS estimates fall by 20%

New major risk - Revenue and earnings growth

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 19%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Price target increased by 9.9% to US$72.00

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Key Executive notifies of intention to sell stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 20%

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?

Politan Capital Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.39 loss

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?

Now 23% undervalued

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Consensus EPS estimates upgraded to US$0.49 loss

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Now 20% undervalued

Independent Chairman notifies of intention to sell stock

Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?

Price target decreased by 13% to US$52.50

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 11%

Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

Is Azenta, Inc. (NASDAQ:AZTA) Worth US$42.5 Based On Its Intrinsic Value?

Consensus EPS estimates fall by 48%

Price target decreased by 8.2% to US$64.60

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023

Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.

Azenta, Inc. Announces Election of Directors

Azenta, Inc., Annual General Meeting, Jan 31, 2023

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations

Azenta Announces Board Resignations

Azenta, Inc. to Report Q4, 2022 Results on Nov 14, 2022

Price target decreased to US$68.20

Azenta, Inc. Announces Matthew McManus Would No Longer Serve as the Companys Chief Operating Officer Effective as of October 14, 2022

Azenta, Inc. (NasdaqGS:AZTA) acquired B Medical Systems S.à R.L. from Navis Capital Partners.

Azenta: Putting Its Cash Hoard To Use

Price target decreased to US$75.40

Executive VP & COO recently bought US$502k worth of stock

Third quarter 2022 earnings: EPS misses analyst expectations

Azenta, Inc. Provides Earnings Guidance for the Fourth Quarter Fiscal 2022

Azenta, Inc. (NasdaqGS:AZTA) entered into an agreement to acquire B Medical Systems S.à R.L. for approximately €460 million.

Azenta to acquire vaccine cold chain firm B Medical Systems for €410M

Brasada Capital - Azenta Life Sciences: No Ordinary Company

Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022

Azenta stock falls postmarket as prelim Q3 revenue misses Street estimates

Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 3000E Growth Index